D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
Apple
AAPL
|
$1.4B |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
$631M |
| 3 |
Pfizer
PFE
|
$432M |
| 4 |
American International
AIG
|
$420M |
| 5 |
Citigroup
C
|
$391M |
Top Sells
Sector Composition
| 1 | Technology | 14.79% |
| 2 | Financials | 12.11% |
| 3 | Healthcare | 11.16% |
| 4 | Consumer Discretionary | 11.07% |
| 5 | Energy | 8.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Pentair
PNR
$17.4B
| $38.8M | 0.07% |
+671,988
| New | +$38.8M |
|
202
NetApp
NTAP
$23.1B
| $38.5M | 0.07% |
+1,019,435
| New | +$38.5M |
|
203
Teva Pharmaceuticals
TEVA
$21.5B
| $38.1M | 0.07% |
+971,861
| New | +$38.1M |
|
|
ITC
204
DELISTED
ITC HOLDINGS CORP
ITC
| $38M | 0.07% |
+416,019
| New | +$38M |
|
205
Zebra Technologies
ZBRA
$15.6B
| $37.8M | 0.07% |
+870,548
| New | +$37.8M |
|
206
SBA Communications
SBAC
$21.7B
| $37.4M | 0.07% |
+504,189
| New | +$37.4M |
|
|
TIBX
207
DELISTED
TIBCO SOFTWARE INC
TIBX
| $36.9M | 0.07% |
+1,726,227
| New | +$36.9M |
|
208
Exact Sciences
EXAS
$9.09B
| $36.4M | 0.07% |
+2,616,002
| New | +$36.4M |
|
209
Thermo Fisher Scientific
TMO
$184B
| $36.4M | 0.07% |
+429,574
| New | +$36.4M |
|
210
AutoZone
AZO
$69.9B
| $36.3M | 0.07% |
+85,770
| New | +$36.3M |
|
|
MDVN
211
DELISTED
MEDIVATION, INC.
MDVN
| $36.3M | 0.07% |
+738,162
| New | +$36.3M |
|
212
Henry Schein
HSIC
$8.29B
| $36.3M | 0.07% |
+379,119
| New | +$36.3M |
|
213
Primerica
PRI
$8.64B
| $36.3M | 0.07% |
+969,004
| New | +$36.3M |
|
|
OCR.PRB
214
DELISTED
OMNICARE CAP TR II SER B 4% TR PFD INCM EQTY REDM SEC PIERS
OCR.PRB
| – | – |
0
| – | – |
|
215
Baidu
BIDU
$33.1B
| $36.2M | 0.07% |
+382,673
| New | +$36.2M |
|
|
AGN
216
DELISTED
ALLERGAN INC
AGN
| $36M | 0.07% |
+427,159
| New | +$36M |
|
217
F5
FFIV
$17.6B
| $35.9M | 0.07% |
+521,214
| New | +$35.9M |
|
|
PARA
218
DELISTED
Paramount Global Class B
PARA
| $35.5M | 0.07% |
+726,180
| New | +$35.5M |
|
219
Adeia
ADEA
$1.63B
| $35.2M | 0.07% |
+1,693,548
| New | +$35.2M |
|
220
Harley-Davidson
HOG
$3.56B
| $35.2M | 0.07% |
+641,332
| New | +$35.2M |
|
|
VPHM
221
DELISTED
VIROPHARMA INC
VPHM
| $35.1M | 0.07% |
+1,224,515
| New | +$35.1M |
|
222
Nucor
NUE
$33.6B
| $34.7M | 0.07% |
+800,000
| New | +$34.7M |
|
|
MCRS
223
DELISTED
MICROS SYSTEMS INC
MCRS
| $34.5M | 0.06% |
+800,000
| New | +$34.5M |
|
224
NOV
NOV
$4.86B
| $34.3M | 0.06% |
+497,540
| New | +$34.3M |
|
225
Wendy's
WEN
$1.96B
| $34.3M | 0.06% |
+5,879,676
| New | +$34.3M |
|